Dapazox (Dapagliflozin)

Dapagliflozin is an SGLT2 inhibitor used to improve glycemic control in adults with type 2 diabetes and to provide proven cardiovascular and renal protection. By blocking the SGLT2 transporter in the kidneys, dapagliflozin promotes urinary glucose excretion, leading to lower blood glucose levels, modest weight loss, and reduced blood pressure. Beyond diabetes, dapagliflozin has become a key therapy in heart failure with reduced or preserved ejection fraction and in chronic kidney disease, regardless of diabetes status. It reduces hospitalization for heart failure, slows kidney disease progression, and improves long‑term outcomes. With once‑daily dosing, weight neutrality, and a low risk of hypoglycemia, dapagliflozin is widely recommended in modern diabetes, heart failure, and CKD guidelines.